Dosing Calculation for Topical Finasteride 2.275 mg/mL Solution
To achieve approximately 0.5 mg of finasteride from a 2.275 mg/mL solution, apply 220 microliters (μL) once daily to the scalp.
Mathematical Calculation
The calculation is straightforward:
- Target dose: 0.5 mg finasteride
- Solution concentration: 2.275 mg/mL
- Required volume: 0.5 mg ÷ 2.275 mg/mL = 0.22 mL = 220 μL
This volume delivers the desired 0.5 mg dose in a single daily application.
Evidence-Based Context
Research with this exact concentration (0.25% finasteride = 2.275 mg/mL) demonstrates that 100-200 μL applied once daily achieves 47-52% scalp DHT suppression while minimizing systemic absorption 1. The 200 μL dose (0.455 mg finasteride) produced only 24-26% serum DHT reduction compared to 44-48% with higher volumes, suggesting better scalp-targeted effects with lower systemic exposure 1.
A Chinese pharmacokinetic study confirmed that 200 μL of this 0.25% solution once daily resulted in plasma finasteride concentrations of only 15.2 pg/mL after single dose and 29.7 pg/mL at steady state—dramatically lower than oral finasteride while maintaining therapeutic scalp effects 2.
Clinical Application Guidelines
For scalp DHT suppression targeting approximately 0.5 mg dose:
- Apply 220 μL once daily to dry scalp
- Apply to affected areas of the scalp only
- Do not blow-dry immediately after application (causes 50% loss of absorption) 3
- Allow at least 4 hours for absorption (75% absorbed within this timeframe) 3
- Apply to dry rather than damp scalp for this formulation to optimize follicular targeting
Important Caveats
The 0.5 mg target dose sits between the studied volumes of 200 μL (0.455 mg) and 300 μL (0.6285 mg). Research shows both doses produce similar scalp DHT suppression (47-54%), but the 200 μL dose offers superior systemic safety profile 1. Consider using 200 μL (0.455 mg) instead of 220 μL as this is the evidence-based dose demonstrating optimal scalp targeting with minimal systemic effects.
For women: Topical finasteride 1% solution has shown efficacy comparable to minoxidil 5% in female pattern hair loss 4, though the evidence base remains limited compared to topical minoxidil, which guidelines establish as first-line therapy 5.
Contraindications: Strict contraception is mandatory for women of childbearing potential due to teratogenic risk (feminization of male fetus) 5.